Ruxolitinib
- Generic Name
- Ruxolitinib
- Brand Names
- Jakafi, Jakavi, Opzelura
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18N6
- CAS Number
- 941678-49-5
- Unique Ingredient Identifier
- 82S8X8XX8H
- Background
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant act...
- Indication
Ruxolitinib is indicated for the treatment of the following conditions:
Topical ruxolitinib is indicated for:
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Chronic Graft-Versus-Host Disease, Non-segmental Vitiligo, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis (PMF), High risk Myelofibrosis, Intermediate risk Myelofibrosis, Mild Atopic dermatitis, Moderate Atopic dermatitis, Refractory Polycythemia vera
- Associated Therapies
- -
Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period
The graft versus host disease market is growing due to the adoption of branded therapies like JAKAFI, IMBRUVICA, ORENCIA, and REZUROCK, a strong pipeline with over 10 new drugs expected to launch, and increased awareness of GvHD management. Innovative treatments and ongoing research aim to address unmet needs in this complex condition.
Rate of Cardiovascular Adverse Events, Myocarditis May Be Low in Trials Assessing ICIs
A systematic review and meta-analysis of 83,315 patients from 589 trials showed low rates of cardiovascular adverse events (CVAEs) and myocarditis in those treated with immune checkpoint inhibitors (ICIs), with no significant differences except for cemiplimab. Dual ICIs increased myocarditis risk, but not CVAEs when combined with chemotherapy or tyrosine kinase inhibitors. Early recognition and treatment are crucial for optimal outcomes, though evidence-based monitoring strategies are lacking. Mortality from myocarditis was 37.7%, with potential reduction through systematic screening and specific treatments.
Incyte wins FDA approval for Niktimvo, considers future
Incyte and Syndax Pharmaceuticals secure FDA approval for Niktimvo, a treatment for chronic graft-versus-host disease, with potential sales of $650 million.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath